$69.99
0.00 (0%)
ImClone Systems, Inc. (NASDAQ:IMCL.DL)
CAPS Rating:
A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.
RSS Headlines
Fool UK
Recs
Take over rumors....company has over-hyped itself in other situations. I suspect they're doing so now. Fool me once, shame on you; fool me twice, shame on me.